Several workers and companies have developed several ureido and sulfonamide based pharmaceuticals for cancer treatment which inhibit CAIX and CAXII (Cabiscol and Levine, 1995; Lomelino and McKenna, 2016). The gene discussed is CA9; the disease is cancer.